<div class="article-image">
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-17-02-2026-shutterstock_2205585127-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/PT-17-02-2026-shutterstock_2205585127-430x241.jpg"/>
                                    
                                    <figcaption>Over 120 patients with haematologic malignancies took part in clinical trials across Canada, Europe, and the US. Credit: Anamaria Mejia / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>ExCellThera and its wholly owned subsidiary Cordex Biologics have received a Status 1 listing from the Neue Untersuchungs- und Behandlungsmethoden (NUB) programme in Germany for Zemcelpro (dorocubicel), also known as UM171 Cell Therapy.</p>



<p>This follows growing clinical evidence for Zemcelpro and interest from 220 hospitals in the country for potential use through the NUB mechanism from 2026.</p><div class="mpu-ad-container">
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div class="in-article-premium-insights mobile-useragent-scalar"><div class="cell large-2 sidebar-scalar mobile-only">
                   <div class="gdm-widget gdm-recommended-reports gdm-pi-recommended-reports gdm-orange-banner recommended-whitepapers"><h3>Go deeper with GlobalData</h3><ul><li><div class="cell small-2"><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div class="cell small-10 details"><div class="category">Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Zimberelimab in Merkel Cell Carcinoma </h4></div> </li><li><div class="cell small-2"><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div class="cell small-10 details"><div class="category">Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Zimberelimab in Multiple Myeloma (Kahler Disease) </h4></div> </li></ul> <div class="about-premium-insights">
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>The European Commission (EC) recently granted conditional marketing authorisation to Zemcelpro for use in adults with haematological malignancies needing allogeneic stem cell transplantation after myeloablative conditioning, where no other suitable donor cells are available.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>With NUB status, Cordex plans to work with German transplant centres on individual NUB applications and expand clinical adoption.</p>



<p>The company will also participate in post-market registries and generate data to facilitate long-term reimbursement and the inclusion of Zemcelpro in clinical guidelines.</p>



<p>The availability of the therapy in individual European countries depends on various factors such as the completion of national reimbursement procedures.</p><div class="gdm-company-profile-unit"> 
                         <div class="gdm-company-profile-unit__profile-container">


            <div class="gdm-company-profile-unit__image-container report-cover" style="width: auto; height: auto">

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div class="gdm-company-profile-unit__form-container">

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper" class="gdm-company-profile-unit__form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Further regulatory submissions are planned for the US, Canada, Switzerland, and the UK. Cordex is pursuing strategic partnerships to support the global commercialisation of Zemcelpro.</p>



<p>The cryopreserved haematopoietic stem cell therapy is composed of UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, both sourced from a single cord blood unit.</p><div id="slot-two"></div>



<p>More than 120 patients with haematologic malignancies took part in clinical trials across Canada, Europe, and the US.</p>



<p>ExCellThera CEO David Millette said: “NUB Status 1 represents a significant milestone for ExCellThera and Cordex and reflects both the innovative nature of Zemcelpro (dorocubicel) and its benefit in addressing a pressing unmet medical need in allogeneic haematopoietic stem cell transplantation.</p>



<p>“Under its initial label, Zemcelpro (dorocubicel) is indicated for patients with life-threatening blood cancers who have limited therapeutic options.”</p>



<p>In August 2025, ExCellThera announced that the EC granted conditional marketing authorisation for its Zemcelpro cell therapy to treat blood cancer patients without access to suitable donor cells.</p>
<div id="slot-three"></div><p></p>



<div class="grid-container">
    
</div>




<p>ExCellThera has secured German NUB Status 1 listing for its therapy Zemcelpro, following positive clinical evidence and interest from 220 hospitals. The European Commission granted conditional marketing authorization for Zemcelpro, aimed at adults with hematological malignancies needing stem cell transplants. The company plans to collaborate with German transplant centers for NUB applications and expand clinical adoption while participating in post-market registries. Further regulatory submissions are planned for the US, Canada, Switzerland, and the UK. CEO David Millette highlighted this milestone as a significant step in addressing unmet medical needs in blood cancer treatment.</p>

ExCellThera secures German NUB Status 1 listing for Zemcelpro